Lazari Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.34M Sell
1,119
-3
-0.3% -$3.06K 0.41% 43
2026
Q1
$1.03M Hold
1,122
0.36% 50
2025
Q4
$1.21M Hold
1,122
0.41% 44
2025
Q3
$856K Buy
1,122
+440
+65% +$327K 0.29% 58
2025
Q2
$532K Sell
682
-4
-0.6% -$3.11K 0.2% 78
2025
Q1
$567K Sell
686
-472
-41% -$393K 0.23% 73
2024
Q4
$894K Buy
1,158
+643
+125% +$532K 0.36% 45
2024
Q3
$456K Buy
515
+38
+8% +$34.2K 0.2% 83
2024
Q2
$432K Buy
477
+177
+59% +$142K 0.19% 83
2024
Q1
$233K Buy
+300
New +$214K 0.13% 94

Other funds holding LLY

Lazari Capital Management's LLY Position: Q2 2026 in Review

Lazari Capital Management reduced its Eli Lilly (LLY) stake by 0.27% in Q2 2026, selling an estimated $3.06K and leaving 1,119 shares worth $1.34M. The position accounts for 0.41% of the portfolio, ranked #43.

Lazari Capital Management first reported a position in LLY in Q1 2024 and has held it in 10 quarters since. 1,844 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Lazari Capital Management held 1,119 shares of Eli Lilly worth $1.34M as of Q2 2026.
  • Lazari Capital Management sold 3 Eli Lilly shares in Q2 2026, an estimated $3.06K.
  • Eli Lilly made up 0.41% of Lazari Capital Management's portfolio in Q2 2026, its #43 holding.
  • Lazari Capital Management first reported a position in Eli Lilly in Q1 2024 and has held it in 10 quarters since.
  • 1,844 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Lazari Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.